CVD in Indigenous Australians
A study carried out in Australia has measured plasma carotenoids concentrations and looked for factors in the indigenous Australian population that affect it, with particular focus on the participants? socioeconomic status.
Indigenous Australians are at increased risk of cardiovascular disease compared to other Australians, a risk that is inversely associated with plasma carotenoids concentrations. As plasma carotenoids are biomarkers for fruit and vegetable intake, poor diet and low socioeconomic status of the indigenous Australians are generally considered to be contributors to this. A study carried out in Australia1 has measured plasma carotenoids concentrations and looked for factors in the indigenous Australian population that affect it, with particular focus on the participants’ socioeconomic status.
Socioeconomic status was determined by self-reported information on education, household size, employment, home ownership and income. Plasma carotenoid levels were measured by high performance liquid chromatography and then linear regression analysis was used to determine relationships between the two factors.
The study found that while self reported intakes of fruit and vegetables were positively associated and intake of takeaway foods inversely associated, adjusting for dietary intake did not completely explain the associations between SES and plasma carotenoids. The concentrations were found to be lower in than the mean for the non-indigenous population.
It was concluded that higher SES did correspond to higher concentrations of plasma carotenoids, so that increasing accessibility of fruit and vegetables as well as reducing smoking rates could improve health, but that there may be additional factors contributing to lower concentrations in Indigenous Australians.
1. A. Hodge et al., BMC Public Health, 11(76) (2011).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
